2May2016 How Much Scrutiny is Biopharma Facing? Not as Much as You Might Think /Luke Timmerman/0/All, Politics, The Edge02 May 2016 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.